Antiseizure Medications for Migraine Prophylaxis
For migraine prevention, use divalproex sodium (500-1500 mg/day) or sodium valproate (800-1500 mg/day) as first-line antiseizure medications, or topiramate as an alternative option. These are the only antiseizure medications with robust evidence supporting their use in migraine prophylaxis 1, 2, 3.
First-Line Antiseizure Medications
Valproate/Divalproex Sodium
- Divalproex sodium: 500-1500 mg/day 1
- Sodium valproate: 800-1500 mg/day 1
- Classified as Level A evidence with strong recommendation for episodic migraine prevention 1, 2, 3
- Particularly effective in patients with prolonged or atypical migraine aura 2
- Critical warnings: Teratogenic effects including neural tube defects; absolutely avoid in women of childbearing potential unless using reliable contraception 2, 4
- Common adverse effects: hair loss, tremor, weight gain, hepatotoxicity 2, 5
- Often not prescribed as first choice due to weight gain and liver toxicity concerns 5
Topiramate
- Dosing: Start low and titrate slowly (specific dosing not provided in guidelines, but typically 25-100 mg/day)
- Strong evidence for both episodic and chronic migraine prevention 3, 6
- Also effective for medication overuse headache 6
- Critical warnings: Severe teratogenicity risk; requires education and contraception planning in women of childbearing potential 5
- Common adverse effects: cognitive impairment, paresthesias, weight loss, kidney stones
- Generally considered first choice among antiseizure medications when valproate is contraindicated 5
Antiseizure Medications NOT Recommended
The following antiseizure medications lack sufficient evidence or have been shown ineffective:
Weak Recommendation Against
Insufficient Evidence (Do Not Use)
- Levetiracetam: Insufficient evidence 3, 8, 9
- Lamotrigine: Not effective 7
- Vigabatrin: Not effective 7
- Clonazepam: Not effective 7
- Acetazolamide: Not effective 7
- Carbamazepine: Insufficient evidence 5
- Zonisamide: Only uncontrolled studies available 5, 8
Emerging Options (Limited Evidence)
- Memantine: Weak recommendation for episodic migraine prevention 3, 9
- May be considered as a later-line option when first-line agents fail
Clinical Implementation Algorithm
Step 1: Assess candidacy for preventive therapy
- ≥2 attacks/month causing disability ≥3 days/month, OR
- Contraindication/failure of acute treatments, OR
- Using abortive medication >2 times/week, OR
- Uncommon migraine conditions (hemiplegic, prolonged aura, migrainous infarction) 1
Step 2: Screen for contraindications
- Women of childbearing potential: Avoid valproate and topiramate unless using reliable contraception 2, 4, 5
- Liver disease: Avoid valproate 2
- Kidney stones: Avoid topiramate
- Cognitive concerns: Avoid topiramate
Step 3: Choose antiseizure medication
- First choice: Topiramate (if no contraindications)
- Alternative: Valproate/divalproex (if not childbearing potential and no liver disease)
- Consider other drug classes first (propranolol, amitriptyline, CGRP inhibitors) as they may have better tolerability profiles 1, 4, 3
Step 4: Initiate and titrate
- Start at low dose
- Titrate slowly until clinical benefit achieved or limited by adverse effects
- Allow 2-3 months for adequate trial before declaring treatment failure 1
Step 5: Monitor and adjust
- Use headache diary to track frequency, severity, duration, and disability 1
- Avoid medication overuse during preventive therapy 1
- After period of stability, consider tapering or discontinuing 1, 4
Critical Pitfalls to Avoid
- Do not use gabapentin despite its common off-label use—evidence shows it is ineffective 3, 7
- Do not prescribe valproate to women of childbearing potential without explicit contraception counseling and documentation 2, 4, 5
- Do not abandon treatment prematurely—allow full 2-3 month trial before switching 1
- Do not use multiple antiseizure medications simultaneously without evidence of added benefit 4
- Do not assume all antiseizure medications work for migraine—only topiramate and valproate have proven efficacy 10, 5, 6
The evidence consistently shows that among antiseizure medications, only valproate and topiramate have Level A evidence for migraine prevention, while numerous other antiseizure medications commonly tried in practice lack supporting data 1, 2, 3, 7.